CSPC Reports 11.5% Revenue Growth in Q1 2024; YL Biologics Announces $1.8B ADC Collaboration with BioNTech
CSPC
Innovative Drug Research and Development, Manufacturer
MediLink
Antibody-Drug Conjugates Developer
BioNTech
Developer of Novel Biologics
CStone Pharmaceuticals
Innovative Oncology Immunotherapy and Precision Medicine Drug Developer
XtalPi
Computation-Driven Innovative Drug R&D Provider
Innovent
High-end Biologics Developer
CSPC PHARMACEUTICAL GROUP LIMITED Releases Latest Report Card.
On May 27, CSPC PHARMACEUTICAL GROUP LIMITED released its Q1 2024 financial report. During the reporting period, the company's revenue was RMB 8.983 billion, representing a year-on-year increase of 11.5%; net profit was RMB 1.612 billion, marking a year-on-year growth of 12.9%.
Chinese-produced innovative drugs continue to go global.
Today, MediLink announced a collaboration with BioNTech for the licensing of ADC technology. BioNTech will obtain exclusive options and corresponding global exclusive licenses for several cutting-edge innovative target ADC products. BioNTech is required to pay a $25 million upfront payment, up to $1.8 billion in milestone payments, and a certain percentage of sales royalties.
CStone Pharmaceuticals also announced that it has granted Ewopharma the commercialization rights for sugemalimab in 18 Central and Eastern European countries. According to the terms of the licensing and commercialization agreement, CStone Pharmaceuticals will receive an upfront payment of up to US$51.3 million, as well as subsequent regulatory and sales milestone payments.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) XtalPi Partners with SPDB Shanghai Branch and SPDB International to Achieve Strategic Cooperation
On May 27, XtalPi announced that it had recently reached a strategic cooperation with Shanghai Branch of SPD Bank and SPDB International. The three parties signed a letter of intent for a credit line of up to 5 billion RMB and exchanged views on various businesses such as fund management, group credit, and ecosystem incubation.
2) MediLink and BioNTech Reach $1.8 Billion Collaboration
On May 27, MediLink announced that it had reached an ADC technology licensing agreement with BioNTech. BioNTech will obtain the exclusive option and corresponding global exclusive license for several cutting-edge innovative target ADC products. BioNTech is required to pay a $25 million upfront payment, up to $1.8 billion in milestone payments, and a certain percentage of sales royalties.
3) CStone Pharmaceuticals' Sugemalimab Goes Overseas to Europe
On May 27, CStone Pharmaceuticals announced that it had granted Ewopharma the commercial rights to sugemalimab in 18 Central and Eastern European countries. According to the terms of the licensing and commercialization agreement, CStone Pharmaceuticals will receive an upfront payment of up to US$51.3 million, as well as subsequent regulatory and sales milestone payments.
/ 02 /
Capital Information
1) CSPC's Q1 net profit increased by 12.9% year-on-year
On May 27, CSPC PHARMACEUTICAL GROUP LIMITED released its Q1 2024 financial report. During the reporting period, the company's revenue reached 8.983 billion yuan, representing an 11.5% year-on-year increase; net profit was 1.612 billion yuan, marking a 12.9% year-on-year growth.
/ 03 /
Pharmaceuticals and Medical Devices Updates
1) Innovent Bio's Tigulixostat Tablets Approved for Clinical Trials
On May 27, according to the CDE official website, Innovent Bio's Tiguoxostat Tablets have been approved for clinical trials, intended to conduct research on the treatment of gout.
2) YINUOWEISHEN FC084CSA Tablets Approved for Clinical Trials
On May 27, according to the CDE official website, Yino Weishen's FC084CSA tablets have been approved for clinical trials. They are intended to be used in combination with other drugs for the treatment of solid tumors such as non-small cell lung cancer, gastric cancer, liver cancer, breast cancer, and sarcoma.
3) CSPC's HCl Cimitinib Tablets Approved for Clinical Trials
On May 27, according to the CDE official website, Runde Medicine's Cimetinib Hydrochloride Tablets have been approved for clinical trials. They are intended to be used in combination with DP303c injection for the treatment of patients with HER2-expressing locally advanced/metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have been previously treated.
4) MediLink's Injectable DB-1305 Approved for Clinical Trials
On May 27, according to the CDE website, MediLink's injectable DB-1305 has been approved for clinical trials, aiming to conduct research on the treatment of advanced/metastatic solid tumors.
5) Yifang Biotech's D-1553 Tablets Approved for Clinical Trials
On May 27, according to the CDE website, D-1553 tablets developed by MediLink have been approved for clinical trials. They are intended to be used in combination with Anlotinib Hydrochloride Capsules for the treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.
6) CSPC's DP303c Injection Approved for Clinical Trials
On May 27, according to the CDE website, CSPC's DP303c injection has been approved for clinical use in combination with Capecitabine for the treatment of HER2-low, unresectable or metastatic breast cancer patients who have received at least one prior line of chemotherapy.
7) Hotgen Bio's Participating Company SGC001 Innovative Drug Clinical Trial Application Approved by FDA
On May 27, Hotgen Biotech announced that the IND application for the innovative drug SGC001, developed by its participating company Shunjing Pharmaceuticals, received FDA approval for emergency treatment of patients with acute myocardial infarction.
8) Langhua Pharmaceutical's Tilorone Hydrochloride Tablets Approved for New Indication
On May 27, according to the NMPA website, Langhua Pharmaceutical's Tilorone Hydrochloride Tablets were approved for a new indication, used to treat excessive daytime sleepiness (EDS) or cataplexy in adolescents and children over 6 years old with narcolepsy.
9) MediLink's EGFR Inhibitor Approved for Clinical Trials by FDA
On May 27, Veshine Bio announced that the FDA approved its EGFR inhibitor WSD0922 for Phase 2 clinical trials in the United States, targeting advanced/metastatic non-small cell lung cancer with C797S mutations that have progressed after first-line osimertinib treatment.
10) Boan Biotech's Denosumab Biosimilar Approved for Marketing
On May 27, Boan Biotech announced that its denosumab biosimilar, Boluoja, has been officially approved for marketing in China. It is indicated for the treatment of giant cell tumor of bone that is inoperable or where surgical resection may lead to severe functional impairment, including adult and adolescent patients with mature skeletal development (defined as having at least one mature long bone and weighing ≥45 kg).
/ 04 /
Overseas Pharmaceutical News
1) Roche BD Department Leadership Change
On May 27, Roche announced that James Sabry, Head of Pharma Partnering, has retired, and Boris Zaïtra, current Head of Group Business Development, will be appointed as the Head of Corporate Business Development.
2) iCell Gene Therapeutics Announces Positive Research Data on CAR-T Therapy for Autoimmune Diseases
Recently, iCell Gene Therapeutics announced that the investigator-initiated clinical trial of BCMA-CD19 cCAR-T cell therapy showed that all systemic lupus erythematosus (SLE)/lupus nephritis (LN) patients who received a sufficient initial dose of cCAR-T treatment tested negative for autoantibodies in their bodies three months post-treatment. At the 46-month follow-up, all patients achieved symptom-free and medication-free remission (MFR).
Text by Huang Kai
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
